European Innovation Council

Precisionlife employs a unique approach to drive innovation in chronic diseases through precision medicine. It uses artificial intelligence to generate deep insights into disease biology, stratifying patient populations for novel drug targets, biomarkers, and repositioning candidates.

Founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, Sequentia Biotech is a bioinformatics company that transforms genomic data into actionable knowledge for academic research, plant/animal breeding, and biomedicine. With over 30 clients and partners, including public/private research centers, companies, and hospitals, Sequentia participates in more than 160 R&D projects and maintains two open-source biodata banks.

Genomika Lietuva is a business that provides cutting-edge, perceptive, and meticulously optimized solutions for the biomedical sciences. It creates DNA storage technologies that allow for high-density storage of significant amounts of information in a remarkably tiny area.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

VIVAN Therapeutics pioneers personalized cancer therapeutics using innovative assay technology. It licenses technology from the Center for Personalized Cancer Therapeutics at Mount Sinai New York, offering a comprehensive, genomics-based drug screening service enabled by blockchain. The company's approach intelligently designs personalized treatments, combining cancer and non-cancer drugs to reduce toxicity and cost.

Enduro Genetics is a technology provider that specializes in enhancing large-scale fermentations through its proprietary synthetic biology technology. The company focuses on improving the performance of fermentation processes by developing a genetic plugin technology that is free of antibiotic resistance genes. This innovation allows for higher yields by enriching spontaneous high producers within the fermentation population, facilitating the production of complex or cellular inhibit products by addressing strain instability. By maximizing the performance of cells derived from production strains, Enduro aims to bolster the competitiveness of both current and future green bioproduction initiatives.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Founded in Paris, France in 2020, Core Biogenesis specializes in developing protein production technologies. The company employs proprietary gene editing and plant biotechnology to significantly lower the cost of producing growth factors, which are crucial molecules in clean meat and cell therapy industries.

NeuroKaire develops personalized psychiatry testing tools. It uses innovative technology to predict the most effective drug treatment for patients, enabling faster recovery, fewer side effects, and lower dosing.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Founded in Paris, France in 2020, Core Biogenesis specializes in developing protein production technologies. The company employs proprietary gene editing and plant biotechnology to significantly lower the cost of producing growth factors, which are crucial molecules in clean meat and cell therapy industries.

Founded in 2012, Computomics specializes in molecular data analysis for crop biotechnology companies and scientists. It offers services such as genome assembly, transcriptome studies, functional annotation, reference-free genotyping, DNA methylation analysis, metagenomic analysis, genomic selection, and crop genome consulting.

Founded in Paris, France in 2020, Core Biogenesis specializes in developing protein production technologies. The company employs proprietary gene editing and plant biotechnology to significantly lower the cost of producing growth factors, which are crucial molecules in clean meat and cell therapy industries.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Founded in 2012, Computomics specializes in molecular data analysis for crop biotechnology companies and scientists. It offers services such as genome assembly, transcriptome studies, functional annotation, reference-free genotyping, DNA methylation analysis, metagenomic analysis, genomic selection, and crop genome consulting.

enGenome is a bioinformatics company that provides accurate omics-based reports to physicians. Its platform automates variant interpretation guidelines, reducing the number of variants of uncertain significance (VUS) and enabling geneticists to detect pathogenic genomic variants with accuracy and speed. This improves diagnosis and treatment processes for patients with genetic diseases.

Founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, Sequentia Biotech is a bioinformatics company that transforms genomic data into actionable knowledge for academic research, plant/animal breeding, and biomedicine. With over 30 clients and partners, including public/private research centers, companies, and hospitals, Sequentia participates in more than 160 R&D projects and maintains two open-source biodata banks.

Founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, Sequentia Biotech is a bioinformatics company that transforms genomic data into actionable knowledge for academic research, plant/animal breeding, and biomedicine. With over 30 clients and partners, including public/private research centers, companies, and hospitals, Sequentia participates in more than 160 R&D projects and maintains two open-source biodata banks.

Genome Biologics is a biotherapeutics company focused on the discovery of therapeutic targets and the development of RNA-targeted therapies, particularly for cardiovascular and cardiometabolic diseases. The company utilizes advanced technology platforms that combine AI-based machine learning with innovative single-cell in vitro and in vivo transgenesis approaches. This integration allows Genome Biologics to identify new therapeutic compounds and repurpose existing ones effectively. By streamlining the drug development process, the company aims to reduce the cost, time, and ethical challenges associated with preclinical research, ultimately facilitating the development of effective treatments for diseases that currently lack viable options.

Perseus Biomics develops microbiome analysis technology to monitor microbiome status and function, quantifying its impact on human life. It offers a benchtop device and microbiome profiling services using optical mapping-based technology, enabling researchers and clinicians to perform strain‑level microbiome analysis with high sensitivity, specificity, and reproducibility.

Perseus Biomics develops microbiome analysis technology to monitor microbiome status and function, quantifying its impact on human life. It offers a benchtop device and microbiome profiling services using optical mapping-based technology, enabling researchers and clinicians to perform strain‑level microbiome analysis with high sensitivity, specificity, and reproducibility.